Latest news with #AmericanAssociationofCancerResearch
Medical News Today
5 days ago
- Health
- Medical News Today
Popular artificial sweetener may negatively affect cancer immunotherapy
Non-sugar, or artificial, sweeteners are widely used to reduce the energy in sweetened foods and drinks, particularly those marketed as diet, or low or no concerns about their possible health effects include links to gastrointestinal problems, metabolic effects, and even increased cancer a study has found that one of the most widely used artificial sweeteners, sucralose, could adversely affect cancer researchers suggest that by changing the gut microbiome, sucralose decreases the effectiveness of immunotherapy for several cancers. Health concerns regarding sucralose have mainly centered around its potential to cause systemic inflammation, metabolic diseases, disruptions in gut microbiota, liver damage, and toxic effects at the cellular a study suggests that people whose diet includes large amounts of sucralose, e.g., from diet drinks, respond less well to cancer immunotherapy than those who consume less or none of the research, which is published in Cancer Discovery, a journal of the American Association of Cancer Research, found that sucralose changed the gut microbiota so bacteria degraded an amino acid, arginine, that immune cells need to be able to destroy cancer are experts worried about sucralose?Sucralose is one of six non-sugar sweeteners approved by the Food and Drug Administration (FDA) for use as additives in the food and drinks industry — the others are aspartame, advantame, neotame, saccharin, and acesulfame potassium (Ace-K).It is made by replacing 3 hydroxyl (oxygen and hydrogen) groups in sucrose (table sugar) molecules with chloride resulting sucralose is up to 650 times sweeter than sucrose and, because people cannot digest it, contains no accessible energy. Therefore, it is widely used to sweeten foods and drinks, as well as being sold as an alternative to sugar for those trying to decrease their energy intake. However, there are concerns, both about its health effects and its efficacy for helping weight loss. In 2023, the World Health Organization (WHO) advised that non-sugar sweeteners should not be used for weight control, saying that: 'Replacing free sugars with NSS [non-sugar sweeteners] does not help with weight control in the long term. […] NSS are not essential dietary factors and have no nutritional value. People should reduce the sweetness of the diet altogether, starting early in life, to improve their health.'Investigating the sucralose-cancer linkDiwakar Davar, MD, associate professor of medicine at the University of Pittsburgh and a medical oncologist and hematologist at UPMC Hillman Cancer Center, senior author of the study, told Medical News Today:'We think this finding is highly significant as it could have immediate positive impacts on cancer patients receiving immunotherapy. The fact that we not only identified sucralose as a potential problem for those receiving immunotherapy, but that we also found a way to fix this problem through arginine supplementation is exciting and something that could be put into clinical practice easily.'According to Jack Jacoub, MD, a board certified medical oncologist and medical director of MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers in Orange County, CA, who was not involved in this research, the findings were significant.'Frankly, this is a superb piece of scientific work,' Jacoub told MNT. 'The authors were able to study preclinical models (mice) and draw conclusions related to the effect of high sucralose intake on T-cell function tumor response to immunotherapy.''They then took this understanding and later tested it in prospective enrolled patients with lung cancer and melanoma. They showed that patients consuming sucralose greater than 0.16 mg/kg/d [milligram per kilogram per day] had inferior response to immunotherapy,' he explained.'Recognizing the significance of arginine on T cell functions they then went back to the mouse model and proved giving it restored T cell function and benefit to immunotherapy in mice. In my opinion, this is high quality evidence suggesting this absolutely needs more exploration,' added decreased immune responseIn their study, the researchers included 132 patients who had undergone immunotherapy or chemoimmunotherapy for advanced/metastatic melanoma or advanced non-small cell lung cancer (NSCLC). They also included 25 patients who had high-risk resectable melanoma. All participants had completed a Diet History Questionnaire III (DHQ III), had received at least 3 months of treatment, had at least one post-treatment imaging study evaluable for response and had been followed up for at least 6 months from the start of the diet questionnaire, researchers calculated each patient's non-nutritive sugar (NNS) intake (mg/day) and divided it by their weight in kg to get a weight-normalized average daily intake of mg/kg/ with melanoma or non-small cell lung cancer who consumed high levels of sucralose (more than 0.16mg/kg/day) had a worse response to immunotherapy, and poorer survival rates, than those with diets low in the artificial whether people undergoing cancer immunotherapy should try to avoid sucralose in their diets, lead author Abby Overacre, PhD, assistant professor in the Department of Immunology at the University of Pittsburgh and UPMC Hillman Cancer Center, told MNT:'We are working on future prospective clinical trials to ask these sorts of questions for patients undergoing immunotherapy. Based on what we know so far, we would recommend that patients minimize intake of non-nutritive sweeteners, particularly sucralose.'Jacoub agreed with this assessment, saying that: 'This is enough information for me to recommend this to my patients. Frankly, we are talking about cancer and giving up diet soda, etc. is not difficult and directly goes to the question patients and their family commonly ask every day when I see them which is 'What can I do to help treat my cancer?'.'It is important to note that the research is still in the early stages, and this may not apply to all cancer microbiota changes reduced T-cell activityThe researchers then carried out tests in two mouse models of cancer to determine how high sucralose consumption reduced the immunotherapy found that mice fed sucralose were resistant to immunotherapy, had significantly increased tumor growth, less CD8+ T cell infiltration, and were more likely to T-cells are immune cells that produce the most powerful anti-cancer response, so their reduced function meant the immunotherapy was less effective. In the sucralose-fed mice, the researchers discovered changes in the gut microbiota, with greater numbers of gram positive bacteria that degraded arginine, an amino acid that is essential for T-cell production.'Gram positive bacteria have been associated with poorer immunotherapy efficacy in previous studies. However, we are very focused and interested in the function of these bacteria in hopes to better understand how they may directly contribute to cancer growth and immunotherapy response.'— Abby Overacre, PhDArginine supplements may counteract sucralose's effectsWhen researchers fed arginine or citrulline (which is metabolized in the body to arginine) to the mice, immunotherapy became effective again. They suggest that arginine or citrulline supplements could be given to people undergoing cancer immunotherapy to counteract the effect of sucralose in their diet. But could people undergoing cancer immunotherapy get enough arginine from their diet?'While there are certainly foods that are higher in arginine, especially in diets associated with better immunotherapy responses (nuts/seeds, poultry, lentils, fruits), a supplement may help those who struggle to achieve a high amount or arginine from diet alone,' Overacre told addition to continuing their research into sucralose and immunotherapy, the researchers hope to investigate whether other non-nutritive sweeteners have similar effects.'We hope that this study can help patients currently receiving immunotherapy. Importantly, this gives patients something they can do themselves or alongside their physicians to potentially improve their overall care.'— Abby Overacre, PhD
Yahoo
29-04-2025
- Health
- Yahoo
Immunotherapy Breakthrough Could Help Some Cancer Patients Avoid Surgery and Chemotherapy
Researchers found that some cancer patients who used a new immunotherapy drug were able to shrink their tumors without undergoing chemotherapy or surgery 103 patients participated in the study, and 84 had 'all signs of their cancer' disappear Researchers said that the immunotherapy drug appeared to only work well with patients who had mismatch repair-deficiency, a unique genetic mutation most often found in patients with colorectal cancer A new immuno-based treatment could treat tumors without cancer patients undergoing surgery or chemotherapy, according to a new study. The research, published in The New England Journal of Medicine and announced at the American Association of Cancer Research (AACR) Annual Meeting, suggested that 92% of patients who used the new immunotherapy drug, dostarlimab, to shrink their tumors ,continued to be cancer-free for at least two years. Treating cancer usually involves a form of immunotherapy alongside chemotherapy and surgery to remove a tumor. However, the new immuno-based treatment would only require a single step — immunotherapy — to treat the cancer by teaching a person's immune system to recognize and attack cancer cells. One hundred and three patients participated in the study, 54 with a variety of "solid tumor cancers," including stomach, endometrial and prostate, and 49 with rectal cancer. Researchers shared in a press release from The Memorial Sloan Kettering Cancer Center that of the 54 patients with a 'variety of cancers," 35 had 'all signs of their cancer' disappear and were using the immuno-based treatment. Related: This Refrigerator Staple Might Lower a Woman's Risk of Colorectal Cancer, New Study Says Per the release, Dr. Andrea Cercek said, "Nearly 2 out of 3 patients with types of cancer other than rectal were able to preserve their organs and their quality of life." 'This is a very significant response, and the results were even better than we had hoped,' Dr. Cercek said. 'We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Maureen Sideris, a patient who was diagnosed with gastroesophageal junction cancer in 2022 and participated in the study, said that the treatment had worked successfully for her, according to the Memorial Sloan Kettering Cancer Center release. 'My husband, Tommy, and I were preparing for the worst,' she recalled in a statement. 'But after being treated with only immunotherapy, I had no evidence of cancer and didn't have to undergo surgery or chemo or radiation. I felt like I won the lottery!' Dr. Cerek reported that '20% of non-rectal cancer patients' who still had to undergo surgery 'saw lower rates of cancer recurrence." She said this suggests that 'even if the effect wasn't a home run, it helped most patients.' Related: Radiation from CT Scans Performed in Just 1 Year Could Lead to Over 100,000 Future Cancer Diagnoses, Study Finds As for all 49 patients with rectal cancer who participated in the study, 'there was no evidence of cancer after immunotherapy,' according to the Memorial Sloan Kettering Cancer Center release. Researchers said that one patient had a 'growth in a lymph node' that was surgically removed but they 'kept their rectum.' However, researchers said that the new treatment comes with its own drawbacks as the immunotherapy drug appeared to only work well with patients who had mismatch repair-deficiency, which means certain cells have mutations when cancer cells separate, according to the National Cancer Institute (NCI). Per the NCI, this mutation 'is most common' in 'colorectal cancer, other types of gastrointestinal cancer, and endometrial cancer" and can also be found in 'cancers of the breast, prostate, bladder and thyroid.' The immunotherapy drug works by targeting cells with this mutation, as the immunotherapy drug can more easily target the many mutations, per the study. 'We're really excited to help more people,' Dr. Cercek said. 'And we are already exploring why rectal tissue seems to have such an extraordinary response to immunotherapy and how we can use that knowledge to help with other cancer types.' Read the original article on People
Business Insider
28-04-2025
- Health
- Business Insider
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at the 2025 American Association of Cancer Research, AACR, Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled 'Preclinical and translational pharmacokinetic modeling of the self-assembling and disassembling, SADA, bispecific fusion protein CD38-SADA for first-in-human pretargeted radioimmunotherapy' characterizes the plasma concentrations of CD38-SADA in animal models over time and a range of doses. Utilizing in vitro binding kinetic parameters and PK data generated from three studies in mice, the study characterized the concentration- and time-dependent equilibrium between CD38-SADA tetramers and monomers Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
